Jump Financial LLC Invests $712,000 in Zymeworks Inc. (NYSE:ZYME)

Jump Financial LLC purchased a new stake in Zymeworks Inc. (NYSE:ZYME - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 48,612 shares of the company's stock, valued at approximately $712,000. Jump Financial LLC owned about 0.07% of Zymeworks as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Sterling Capital Management LLC boosted its stake in Zymeworks by 781.5% during the fourth quarter. Sterling Capital Management LLC now owns 1,719 shares of the company's stock worth $25,000 after buying an additional 1,524 shares during the period. AlphaQuest LLC lifted its stake in Zymeworks by 480.2% in the fourth quarter. AlphaQuest LLC now owns 2,808 shares of the company's stock worth $41,000 after acquiring an additional 2,324 shares during the last quarter. FMR LLC increased its holdings in Zymeworks by 84.2% in the third quarter. FMR LLC now owns 3,336 shares of the company's stock valued at $42,000 after buying an additional 1,525 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Zymeworks in the fourth quarter valued at approximately $151,000. Finally, New York State Common Retirement Fund grew its position in shares of Zymeworks by 42.7% in the 4th quarter. New York State Common Retirement Fund now owns 13,371 shares of the company's stock valued at $196,000 after buying an additional 4,000 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ZYME has been the subject of a number of research reports. HC Wainwright boosted their price objective on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Monday, March 10th. Citigroup lifted their price target on Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, March 7th. Finally, Lifesci Capital initiated coverage on shares of Zymeworks in a research report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Zymeworks has an average rating of "Moderate Buy" and an average price target of $21.00.

Insider Buying and Selling at Zymeworks

In other Zymeworks news, Director Ecor1 Capital, Llc purchased 468,356 shares of Zymeworks stock in a transaction on Thursday, March 13th. The shares were purchased at an average cost of $12.48 per share, with a total value of $5,845,082.88. Following the completion of the transaction, the director now directly owns 16,802,141 shares in the company, valued at approximately $209,690,719.68. This represents a 2.87 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders acquired 1,350,347 shares of company stock worth $16,137,499 in the last 90 days. 1.92% of the stock is owned by company insiders.

Zymeworks Stock Performance

NYSE ZYME traded up $0.05 during mid-day trading on Friday, reaching $12.57. 370,378 shares of the stock were exchanged, compared to its average volume of 616,997. The stock has a market capitalization of $874.58 million, a PE ratio of -8.38 and a beta of 1.18. Zymeworks Inc. has a 1-year low of $7.97 and a 1-year high of $17.70. The business's fifty day simple moving average is $12.13 and its 200 day simple moving average is $13.51.

Zymeworks Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.